Qualigen Therapeutics Inc
Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS tha… Read more
Qualigen Therapeutics Inc (QLGN) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.056x
Based on the latest financial reports, Qualigen Therapeutics Inc (QLGN) has a cash flow conversion efficiency ratio of -0.056x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.14 Million) by net assets ($38.55 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Qualigen Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Qualigen Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Qualigen Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Qualigen Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mehadrin
TA:MEDN
|
-0.080x |
|
Nepra Foods Inc
PINK:NPRFF
|
0.151x |
|
Telefonica Chile S.A.
SN:CTC
|
-0.101x |
|
ROCKWELL AUTOMATION (RWL.SG)
STU:RWL
|
0.118x |
|
FirstCaution SA
PA:MLFIR
|
N/A |
|
Tempest Minerals Ltd
AU:TEM
|
0.034x |
|
Enzon Pharmaceuticals Inc
OTCQX:ENZN
|
1.125x |
|
COFLE S.P.A.
F:Y9A
|
N/A |
Annual Cash Flow Conversion Efficiency for Qualigen Therapeutics Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Qualigen Therapeutics Inc from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $2.68 Million | $-6.33 Million | -2.362x | -148.22% |
| 2023-12-31 | $-2.10 Million | $-10.30 Million | 4.898x | +424.16% |
| 2022-12-31 | $8.77 Million | $-13.25 Million | -1.511x | -69.93% |
| 2021-12-31 | $16.56 Million | $-14.73 Million | -0.889x | -66.77% |
| 2020-12-31 | $18.29 Million | $-9.76 Million | -0.533x | -1123.08% |
| 2019-12-31 | $1.10 Million | $57.33K | 0.052x | +103.67% |
| 2018-12-31 | $9.39 Million | $-13.33 Million | -1.420x | -286.43% |
| 2017-12-31 | $20.13 Million | $-7.40 Million | -0.368x | +90.08% |
| 2016-12-31 | $4.10 Million | $-15.21 Million | -3.707x | -851.36% |
| 2015-12-31 | $14.68 Million | $-5.72 Million | -0.390x | +42.48% |
| 2014-12-31 | $1.71 Million | $-1.16 Million | -0.677x | -112.12% |
| 2013-12-31 | $-350.25K | $-1.96 Million | 5.587x | +271.69% |
| 2012-12-31 | $946.03K | $-3.08 Million | -3.254x | -- |